Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
|
30702464 |
2020 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Approximately 90% of endometrioid carcinomas have at least one mutation in the genes CTNNB1, KRAS, PTEN, or PIK3CA.
|
30315273 |
2019 |
Carcinoma, Endometrioid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SOX17, β-catenin and CyclinD1 expression in the endometrioid adenocarcinoma and influence of 5-AZA on expression.
|
31543512 |
2019 |
Carcinoma, Endometrioid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Electronic databases were searched for studies evaluating β-catenin immunohistochemistry in normal endometrium (NE), benign and/or premalignant EH, and endometrioid carcinoma (EC).
|
31403731 |
2019 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ECCs less frequently harboured mutations affecting CTNNB1 and PTEN but more frequently harboured PPP2R1A and TP53 mutations than non-POLE endometrioid carcinomas from The Cancer Genome Atlas (TCGA).
|
28718916 |
2017 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The KRAS gene was most often mutated in carcinomas next to hyperplastic endometrium, whereas PIK3CA and CTNNB1 mutations were found in endometrioid carcinomas with adjacent atrophic endometrium.
|
28203752 |
2017 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By contrast, CTNNB1 mutations are significantly different in low-grade ovarian endometrioid carcinomas (53%) compared with low-grade endometrial endometrioid carcinomas (28%) (P<0.0057).
|
23765252 |
2014 |
Carcinoma, Endometrioid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aberrant nuclear beta-catenin expression in the spindle or corded cells in so-called corded and hyalinized endometrioid carcinomas. Another critical role of the unique morphological feature.
|
19085831 |
2009 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A review of the literature indicated that beta-catenin mutations are characteristic of well-differentiated endometrioid carcinomas, since they were present in nearly 60% of grade I but in less of 3% of grade III tumours.
|
16429393 |
2006 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Morule-like features were seen in WDFAs. beta Catenin gene mutation was demonstrated in one EC and PB, and in two WDFAs.
|
16394288 |
2006 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current data indicate that each of these histologic subtypes is associated with distinct morphologic and molecular genetic alterations: high-grade serous and possibly endometrioid carcinomas most probably arise from surface epithelial inclusion glands with TP53 mutations and dysfunction of BRCA1 and/or BRCA2; low-grade serous carcinomas probably arise in a stepwise fashion in an adenoma-borderline tumor-carcinoma sequence from typical to micropapillary borderline tumors to low-grade invasive serous carcinoma via activation of the RAS-RAF signaling pathway secondary to mutations in KRAS and BRAF; mucinous carcinomas arise via an adenoma-borderline tumor-carcinoma sequence with mutations in KRAS; low-grade endometrioid carcinomas arise from endometriosis via mutations in CTNNB1 (the gene encoding beta-catenin) and PTEN.
|
15761464 |
2005 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nuclear immunoreactivities for beta -catenin and CTNNB1 mutations were restricted to independent uterine and ovarian tumors and were absent in all of the metastatic tumors, providing direct evidence for a divergence of molecular oncogenetic mechanisms in the subset of synchronous endometrioid carcinomas.
|
16021566 |
2005 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most frequent genetic alteration in endometrioid carcinoma is PTEN inactivation by mutation, followed by microsatellite instability (MIN) and mutations of K-ras and beta-catenin.
|
14747944 |
2004 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PTEN: and beta-catenin mutations constitute the predominant genetic alterations in endometrioid carcinomas of the endometrium.
|
15492994 |
2004 |
Carcinoma, Endometrioid
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been suggested that the former tumors have the same molecular alterations (microsatellite instability [MSI], PTEN, and beta-catenin) described in endometrioid carcinomas of the uterus.
|
15668893 |
2004 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutations were identified in 15 ECs (20.5%), all of them endometrioid carcinomas (15 of 59; 25.4%).
|
11957146 |
2002 |
Carcinoma, Endometrioid
|
0.100 |
Biomarker
|
disease |
LHGDN |
CTNNB1 mutations were identified in 15 ECs (20.5%), all of them endometrioid carcinomas (15 of 59; 25.4%).
|
11957146 |
2002 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma.
|
11048799 |
2000 |
Carcinoma, Endometrioid
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the univariate and multivariate survival analyses, beta-catenin nuclear expression was selected as an indicator of good prognosis, because no patient whose tumor expressed beta-catenin in the nuclei showed relapses or died, in contrast to the 19 relapses and deaths among patients with tumors that only had beta-catenin membranous expression, including three of the four patients with endometrioid carcinomas.
|
10433945 |
1999 |
Carcinoma, Endometrioid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas.
|
10391090 |
1999 |